Skip to content

Dolasetron

    Brands

    DEA Class; Rx

    Common Brand Names; Anzemet

    • Antiemetics, Selective 5-HT3 Antagonist

    Oral/intravenous antiemetic; 5-HT3 receptor antagonist
    Oral tablet used for prevention of chemotherapy-induced nausea/vomiting; injection used for prevention and treatment of PONV
    Risk of dose-dependent QT prolongation and torsades de pointes

    Indicated for the treatment of Cancer Chemotherapy Induced Nausea & Vomiting

    Indicated for prevention and treatment of postoperative nausea and vomiting (PONV)

    Hypersensitivity

    Coadministration with apomorphine; combination reported to cause profound hypotension and loss of consciousness

    IV administration for chemotherapy-induced nausea/vomiting (CINV) because of risk for QT, PR, and QRS prolongation

    • Headache
    • Diarrhea
    • Dizziness
    • Drowsiness
    • Fatigue
    • Bradycardia
    • HTN
    • Hypotension
    • Tachycardia
    • Abdominal pain
    • Dyspepsia
    • Abnormal liver function
    • Chills
    • Fever
    • Oliguria
    • Urinary retention
    • Pain
    • Pruritus

    Patients at risk for prolongation of cardiac conduction intervals, particularly long QTc interval, congenital long QT syndrome, uncorrected hypokalemia or hypomagnesemia, or receiving other QT-prolonging drugs

    Serotonin syndrome reported with 5-HT3 receptor antagonists alone but particularly with concomitant use of serotonergic drugs including SSRIs, SNRIs, MAO inhibitors, lithium, tramadol, methylene blue IV, and mirtazapine

    Correct hypokalemia and hypomagnesemia before administration

    Use electrocardiogram (ECG) monitoring in patients with congestive heart failure, bradycardia, underlying heart disease, renal impairment, or who are elderly

    Pregnancy Category: B

    Lactation: not known whether distributed into breast milk, use caution

    Adults

    100 mg/dose PO; 12.5 mg/dose IV (for prevention/treatment of post-operative nausea/vomiting). Information on maximum total daily dose is unavailable.

    Geriatric

    100 mg/dose PO; 12.5 mg/dose IV (for prevention/treatment of post-operative nausea/vomiting). Information on maximum total daily dose is unavailable.

    Adolescents

    1.8 mg/kg PO (Max: 100 mg/dose) for prevention of chemotherapy-induced nausea/vomiting; 0.35 mg/kg IV (Max: 12.5 mg/dose) for prevention/treatment of post-op nausea/vomiting.

    Children

    2 years or older: 1.8 mg/kg PO (Max: 100 mg/dose) for prevention of chemotherapy-induced nausea/vomiting; 0.35 mg/kg IV (Max: 12.5 mg/dose) for prevention/treatment of post-op nausea/vomiting.
    Younger than 2 years: Safety and efficacy have not been established.

    Infants

    Safety and efficacy have not been established.

    Neonates

    Safety and efficacy have not been established.

    Dolasetron mesylate

    injectable solution

    • 20mg/mL

    tablet

    • 50mg
    • 100mg